Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024
Rhea-AI Summary
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease therapies, has rescheduled its third quarter 2024 financial results announcement to November 13, 2024. The date change accommodates SEC filing rules affected by the November 11 federal holiday. The company will host a webcast at 8:30 a.m. Eastern Time to discuss results and provide a corporate update. The webcast will be accessible on Liquidia's website and archived for one year.
Positive
- None.
Negative
- None.
MORRISVILLE, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today it will now report its third quarter 2024 financial results on Wednesday, November 13, 2024. The date has been moved to accommodate for SEC filing rules impacted by the federal holiday observed on Monday, November 11, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.
The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
FAQ
When will Liquidia (LQDA) report Q3 2024 earnings?
What time is Liquidia's (LQDA) Q3 2024 earnings call?
Why did Liquidia (LQDA) change its Q3 2024 earnings report date?
Where can I access Liquidia's (LQDA) Q3 2024 earnings webcast?
